
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a US$40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday.
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a US$40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday.